Aberrant expression of p27(Kip1) is associated with malignant transformation of the rat urinary bladder epithelium.
Alteration in cell cycle regulators is considered to play an important role in carcinogenesis. In order to cast light on changes in reversible hyperplastic and irreversible tumorigenic lesions in the rat urinary bladder, expression of p27(Kip1), cyclin D1 and cyclin E proteins was sequentially compared. In the first study, 3% uracil was fed for 4 weeks to cause urinary calculi and consequent hyperplasia and papillomatosis, both regressing after withdrawal of the insult. Compared with normal bladder epithelium, in papillomatosis at week 4, the BrdU index and immunohistochemical positivities for cyclin D1 and cyclin E were significantly elevated, whereas values for p27(Kip1) tended to be reduced. One week after withdrawal of uracil, the BrdU index and positivities for cyclin D1 and cyclin E were decreased to below the control levels, while positivity for p27(Kip1) was dramatically increased, with a strong staining intensity. In a second study, rats were initiated with a bladder carcinogen, N-butyl-N-(4-hydroxybutyl)nitrosamine for 4 weeks, then fed 3% uracil for 8 weeks. During this latter period, expression of cyclin D1, cyclin E and p27(Kip1) in hyperplastic urothelium were comparable with those in the first study. One week after withdrawal of uracil, most urothelial lesions regressed, showing high p27(Kip1) and low cyclin D1 and cyclin E staining. Two weeks after uracil withdrawal, transitional cell carcinomas, with a low p27(Kip1) and high cyclin D1 and cyclin E staining pattern, could be easily distinguished from surrounding regressing epithelium. These data indicate that during regression of papillomatosis after cessation of a proliferative stimulus, expression of p27(Kip1)is elevated, accompanied by a lowering of cyclin D1 and cyclin E. In irreversible tumorous bladder lesions, on the other hand, persistent low expression of p27(Kip1) and elevated cyclin D1 and cyclin E are characteristic.
Ogawa
K
K
First Department of Pathology, Nagoya City University, Medical School, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. kogawa@med.nagoya-cu.ac.jp
Kimoto
N
N
Asamoto
M
M
Nakanishi
M
M
Takahashi
S
S
Shirai
T
T
D000818:Animals; D001973:Bromodeoxyuridine / Q000378:metabolism; D002085:Butylhydroxybutylnitrosamine / Q000633:toxicity; D018797:Cell Cycle Proteins; D019938:Cyclin D1 / Q000032:analysis; D019927:Cyclin E / Q000032:analysis; D050760:Cyclin-Dependent Kinase Inhibitor p27; D008297:Male; D008869:Microtubule-Associated Proteins / Q000032:analysis*; D010212:Papilloma / Q000139:chemically induced / Q000737:chemistry* / Q000473:pathology; D051381:Rats; D011916:Rats, Inbred F344; D025521:Tumor Suppressor Proteins; D014498:Uracil / Q000633:toxicity; D001744:Urinary Bladder Calculi / Q000139:chemically induced; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000737:chemistry* / Q000473:pathology
C493962:Cdkn1b protein, rat; D018797:Cell Cycle Proteins; D019927:Cyclin E; D008869:Microtubule-Associated Proteins; D025521:Tumor Suppressor Proteins; D019938:Cyclin D1; D050760:Cyclin-Dependent Kinase Inhibitor p27; D002085:Butylhydroxybutylnitrosamine; D014498:Uracil; D001973:Bromodeoxyuridine